With an aim to improve clinical benefits in a wider population of GC patients, our findings suggested that the expression of ligands for Tim-3 and Lag-3 on tumor cells serve as the potential biomarker to detect the candidates for anti-PD-1 therapy in GC patients, and the combinatorial immunotherapy with ICIs targeting for PD-1, Tim-3, and Lag-3 has a therapeutic potential in GC patients. This evidence concerns the gene HAVCR2 and neoplasm.